KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Work In Process (2016 - 2017)

Amgen has reported Work In Process over the past 5 years, most recently at $1.6 billion for Q2 2017.

  • Quarterly results put Work In Process at $1.6 billion for Q2 2017, changed N/A from a year ago — trailing twelve months through Jun 2017 was $1.6 billion (changed N/A YoY), and the annual figure for FY2016 was $1.6 billion, up 5.17%.
  • Work In Process for Q2 2017 was $1.6 billion at Amgen, up from $1.5 billion in the prior quarter.
  • Over the last five years, Work In Process for AMGN hit a ceiling of $2.1 billion in Q4 2013 and a floor of $1.3 billion in Q2 2015.
  • Median Work In Process over the past 5 years was $1.6 billion (2014), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Work In Process: fell 28.1% in 2015 and later rose 5.17% in 2016.
  • Amgen's Work In Process stood at $2.1 billion in 2013, then decreased by 24.85% to $1.6 billion in 2014, then fell by 1.42% to $1.5 billion in 2015, then rose by 5.17% to $1.6 billion in 2016, then increased by 0.62% to $1.6 billion in 2017.
  • The last three reported values for Work In Process were $1.6 billion (Q2 2017), $1.5 billion (Q1 2017), and $1.6 billion (Q4 2016) per Business Quant data.